Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 3/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781044 | 0.84 | ENPP2 (0.60) | ENPP2ACHELPLLIPGF11 | |
| SCHEMBL14217865 | 0.81 | ENPP2 (0.38) | ENPP2TTRLPLLIPGIDO1 | |
| SCHEMBL12247400 | 0.81 | LPL (0.48) | ENPP2TTRLPLLIPG | |
| SCHEMBL29209517 | 0.78 | ENPP2 (0.52) | ENPP2RECQLTTRLPLLIPG | |
| SCHEMBL177673 | 0.78 | ENPP2 (0.52) | ENPP2RECQLTTR | |
| SCHEMBL92904 | 0.78 | TSHR (0.50) | ACHERECQLTTRIDO1FFAR4 | |
| SCHEMBL28957378 | 0.78 | ACHE (0.48) | ACHERECQLTTRIDO1FFAR4 | |
| SCHEMBL16687395 | 0.74 | ENPP2 (0.50) | ENPP2ACHELPLLIPGIDO1 | |
| SCHEMBL16021767 | 0.74 | ENPP2 (0.50) | ENPP2ACHELPLLIPGF11 | |
| SCHEMBL31062311 | 0.74 | ENPP2 (0.50) | ENPP2ACHELPLLIPGIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | RAPT THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3802544-A1 | PYRAZOLO-PYRIMIDIN-AMINO-CYCLOALKYL COMPOUNDS AND THEIR THERAPEUTIC USES | RAPT Therapeutics, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ENPP2 517/4885ACHE 849/4885RECQL 13/4885 |
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | GLS, GLS2, TK2 | ENPP2 145/4885ACHE 4000/4885RECQL 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.